Business
Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements
Physician-run radiation oncology innovator also to research new indications and broaden the market for SRT to include inflammatory diseases BOCA RATON, Fla.,
About this update from Sensus Healthcare, Inc.
[{"type":"text","content":"Physician-run radiation oncology innovator also to research new indications and broaden the market for SRT to include inflammatory diseases BOCA RATON, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a new multi-faceted collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, Calif. Under the collaboration, CureRays will provide Sensus’ dermatology customers with oversight and supervision to assure patient safety, quality, reliability of outcomes and conformance with regulatory requirements, in particular in states where regulations covering the use of ionizing radiation have been tightened. In addition, CureRays will research new indications for Sensus’ superficial radiotherapy (SRT and IG-SRT), including inflammatory diseases. “This collaboration is the culmination of several years of discussion that started early in the COVID-19 pandemic, when we learned that Drs. Khan and Hess were treating COVID pneumonia with low-dose radiotherapy for infectious and inflammatory diseases. We were anxious to help stem fatalities in any way we could, and we’ve been impressed with their commitment to patient care. CureRays is well-versed in our SRT-100 Vision® (IG-SRT) system, which they are utilizing to treat skin cancer and keloids,” commented Joe Sardano, chairman and chief executive officer of Sensus. “CureRays’ expertise in radiotherapy and their commitment to continuing education led us to engage them to help our dermatologist customers navigate the complex and changing requirements of radiotherapy,” he added. “In addition, we are thrilled to support their efforts to expand the use of our products and broaden our markets, beginning with arthritis.” CureRays is led by Mohammad K. Khan, M.D., Ph.D., Professor of Medicine, Department of Radiation Oncology at the Emory University School of Medicine, and Clayton Hess, M.D., M.P.H., Medical Director, Radiation Oncology at Sierra Nevada Memorial Hospital in Grass Valley. Dr. Khan serves on the Sensus Medical Advisory Board and Dr. Hess treats patients with a recently-purchased SRT 100-Vision (IG-SRT) at CureRays’ Grass Valley facility...